Molecular Lymph Node Staging with One-Step Nucleic Acid Amplification and its Prognostic Value for Patients with Colon Cancer: The First Follow-up Study

Publikation

Molecular Lymph Node Staging with One-Step Nucleic Acid Amplification and its Prognostic Value for Patients with Colon Cancer: The First Follow-up Study

Wissenschaftlicher Artikel/Review - 29.01.2021

Weixler Benjamin, Viehl Carsten T, Van de Velde Cornelis J H, Vahrmeijer Alexander, Zettl Andreas, Gueller Ulrich, Demartines Nicolas, Warschkow Rene, Teixeira da Cunha Sofia, Zuber Markus

Zitation

Weixler B, Viehl C, Van de Velde C, Vahrmeijer A, Zettl A, Gueller U, Demartines N, Warschkow R, Teixeira da Cunha S, Zuber M. Molecular Lymph Node Staging with One-Step Nucleic Acid Amplification and its Prognostic Value for Patients with Colon Cancer: The First Follow-up Study. World J Surg 2021; 45:1526-1536.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

World J Surg 2021; 45

Veröffentlichungsdatum

29.01.2021

ISSN (Druck)

0364-2313

eISSN (Online)

1432-2323

Seiten

1526-1536

Kurzbeschreibung/Zielsetzung

BACKGROUND
Molecular lymph node workup with one-step nucleic acid amplification (OSNA) is a validated diagnostic adjunct in breast cancer and also appealing for colon cancer (CC) staging. This study, for the first time, evaluates the prognostic value of OSNA in CC.

PATIENTS AND METHODS
The retrospective study includes patients with stage I-III CC from three centres. Lymph nodes were investigated with haematoxylin and eosin (H&E) and with OSNA, applying a 250 copies/μL threshold of CK19 mRNA. Diagnostic value of H&E and OSNA was assessed by survival analysis, sensitivity, specificity and time-dependent receiver operating characteristic curves.

RESULTS
Eighty-seven patients were included [mean follow-up 53.4 months (± 24.9)]. Disease recurrence occurred in 16.1% after 19.8 months (± 12.3). Staging with H&E independently predicted worse cancer-specific survival in multivariate analysis (HR = 10.77, 95% CI 1.07-108.7, p = 0.019) but not OSNA (HR = 3.08, 95% CI 0.26-36.07, p = 0.197). With cancer-specific death or recurrence as gold standard, H&E sensitivity was 46.7% (95% CI 21.3-73.4%) and specificity 84.7% (95% CI 74.3-92.1%). OSNA sensitivity and specificity were 60.0% (95% CI 32.3-83.7%) and 75.0% (95% CI 63.4-84.5%), respectively.

CONCLUSIONS
In patients with CC, OSNA does not add relevant prognostic value to conventional H&E contrasting findings in other cancers. Further studies should assess lower thresholds for OSNA (< 250 copies/μL).